Key Points
-
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF)-mediated pro-angiogenic signalling pathways are producing demonstrable clinical benefit for an increasing number of cancer types. However, in some cases (both in humans and in mouse models of cancer) anti-angiogenic therapies produce initial responses followed almost inevitably by progression, thereby affording appreciable but limited survival advantage. In other cases there is no objective benefit. Increasing evidence supports the proposition that progression and mortality following a period of benefit reflects an adaptive response by tumours, manifesting 'evasive resistance' to angiogenesis inhibitors. By contrast, patients for whom there is no tangible benefit indicate that an intrinsic resistance to angiogenesis inhibitors exists.
-
Evasive resistance to VEGF pathway inhibitors (and arguably other angiogenesis inhibitors) involves a number of distinct and interrelated mechanisms that may be variably important. The emergent mechanisms of evasive resistance include revascularization consequent to upregulation of alternative pro-angiogenic signals; protection of the tumour vasculature either by recruiting pro-angiogenic inflammatory cells or by increasing protective pericyte coverage; accentuated invasiveness of tumour cells into local tissue to co-opt normal vasculature; and increased metastatic seeding and tumour cell growth in lymph nodes and distant organs.
-
Intrinsic resistance is likely to involve similar molecular and cellular mechanisms to those that mediate evasive resistance. Whereas rapid adaptive responses (fast evasion) may underlie some cases of apparent intrinsic resistance, there is evidence to suggest that certain tumours, owing to their stage of progression, treatment history, genomic constitution and/or host genotype, may have a pre-existing tumour microenvironment that conveys such indifference.
-
If the postulate of evasive and intrinsic resistance to angiogenesis inhibitors is further validated in preclinical and clinical investigations, we foresee a future of cancer therapeutics in which combinatorial strategies involving angiogenesis inhibition are integrated with drugs targeting resistance mechanisms to afford enduring efficacy.
Abstract
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance, an adaptation to circumvent the specific angiogenic blockade; and intrinsic or pre-existing indifference. Multiple mechanisms can be invoked in different tumour contexts to manifest both evasive and intrinsic resistance, motivating assessment of their prevalence and importance and in turn the design of pharmacological strategies that confer enduring anti-angiogenic therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353 (1996).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007).
Ferrara, N., Hillan, K. J. & Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328–335 (2005).
Jain, R. K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19, 7–16 (2005).
Smith, J. K., Mamoon, N. M. & Duhe, R. J. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14, 175–225 (2004).
Ferrara, N., Damico, L., Shams, N., Lowman, H. & Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26, 859–870 (2006).
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T. Jr, Feinsod, M. & Guyer, D. R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).
Apte, R. S. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin. Pharmacother. 9, 499–508 (2008).
Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol. 26, 127–132 (2008).
Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev. Cancer 8, 579–591 (2008).
Avraamides, C. J., Garmy-Susini, B. & Varner, J. A. Integrins in angiogenesis and lymphangiogenesis. Nature Rev. Cancer 8, 604–617 (2008).
Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev. Cancer 8, 618–631 (2008).
Neufeld, G. & Kessler, O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nature Rev. Cancer 8, 632–645 (2008).
Yan, M. & Plowman, G. D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13, 7243–7246 (2007).
Thurston, G., Noguera-Troise, I. & Yancopoulos, G. D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nature Rev. Cancer 7, 327–331 (2007).
Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825–831 (2007).
Petit, I., Jin, D. & Rafii, S. The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299–307 (2007).
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
Erber, R. et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18, 338–340 (2004).
Pietras, K., Pahler, J., Bergers, G. & Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008).
Saltz, L. B. et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557–4561 (2007).
Shojaei, F. & Ferrara, N. Antiangiogenic therapy for cancer: an update. Cancer J. 13, 345–348 (2007).
Kindler, H. L. et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC). J. Clin. Oncol. 25, 4508 (2007).
Miller, K. D., Sweeney, C. J. & Sledge, G. W. Jr. Can tumor angiogenesis be inhibited without resistance? EXS 2005, 95–112 (2005).
Gatenby, R. A. & Gillies, R. J. A microenvironmental model of carcinogenesis. Nature Rev. Cancer 8, 56–61 (2008).
Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31–36 (1991).
Kerbel, R. S. A cancer therapy resistant to resistance. Nature 390, 335–336 (1997).
Kerbel, R. S. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20, 79–86 (2001).
Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005). This study demonstrates the existence of evasive resistance by alternative pro-angiogenic signalling.
Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133–146 (2003).
Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
Kerbel, R. S. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8, 269–271 (2005).
Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnol. 25, 911–920 (2007). This study reveals CD11b+Gr1+ monocytes to be mediators of intrinsic resistance to anti-VEGF treatment in murine transplant tumours.
Glade Bender, J., Cooney, E. M., Kandel, J. J. & Yamashiro, D. J. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist. Updat. 7, 289–300 (2004).
Mizukami, Y. et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nature Med. 11, 992–997 (2005).
Gorre, M. E. & Sawyers, C. L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr. Opin. Hematol. 9, 303–307 (2002).
O'Connor, R., Clynes, M., Dowling, P., O'Donovan, N. & O'Driscoll, L. Drug resistance in cancer — searching for mechanisms, markers and therapeutic agents. Expert Opin. Drug Metab. Toxicol. 3, 805–817 (2007).
Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306–314 (2000). First study demonstrating vessel co-option of tumour cells in response to anti-VEGF therapy.
Fernando, N. T. et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin. Cancer Res. 14, 1529–1539 (2008).
Kadenhe-Chiweshe, A. et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol. Cancer Res. 6, 1–9 (2008).
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007). This clinical study describes the ability of the pan-VEGFR inhibitor AZD1271 to normalize tumour vessels in recurrent patients with glioblastoma using MRI technology. FGF2 and SDF1α blood levels increased when tumours escaped treatment.
Bertolini, F., Mancuso, P., Shaked, Y. & Kerbel, R. S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today 12, 806–812 (2007).
Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Rev. Cancer 6, 835–845 (2006).
Bocci, G. et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64, 6616–6625 (2004).
Ebos, J. M., Lee, C. R., Christensen, J. G., Mutsaers, A. J. & Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069–17074 (2007).
Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997).
Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71–78 (2004).
De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211–226 (2005).
Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nature Med. 8, 841–849 (2002).
Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284–290 (2006).
Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409–421 (2004).
Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175–189 (2006).
Du, R. et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206–220 (2008). This study reveals that monocytic cells from the bone marrow are sufficient to drive neovascularization in GBM. Impairment of VEGF signalling leads to an adaptive pro-invasive tumour phenotype, which can be directly blocked by VEGF.
Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Med. 10, 858–864 (2004).
De Falco, E. et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104, 3472–3482 (2004).
Aghi, M., Cohen, K. S., Klein, R. J., Scadden, D. T. & Chiocca, E. A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 66, 9054–9064 (2006).
Dewhirst, M. W., Cao, Y. & Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev. Cancer 8, 425–437 (2008).
Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785–1787 (2006). This study reveals that influx of bone marrow-derived endothelial progenitors is an essential step in re-neovascularization of tumours that have undergone treatments with vascular disrupting agents.
Sathornsumetee, S. et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26, 271–278 (2008).
Allt, G. & Lawrenson, J. G. Pericytes: cell biology and pathology. Cells Tissues Organs 169, 1–11 (2001).
Gerhardt, H. & Betsholtz, C. Endothelial–pericyte interactions in angiogenesis. Cell Tissue Res. 314, 15–23 (2003).
Bergers, G. & Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 7, 452–464 (2005).
Jain, R. K. & Booth, M. F. What brings pericytes to tumor vessels? J. Clin. Invest. 112, 1134–1136 (2003).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).
Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788–1795 (2007).
Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).
Benjamin, L., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591–1598 (1998).
Darland, D. C. et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol. 264, 275–288 (2003).
Song, S., Ewald, A. J., Stallcup, W., Werb, Z. & Bergers, G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol. 7, 870–879 (2005).
Hirschi, K. K. & D'Amore, P. A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 79, 419 (1997).
Orlidge, A. & D'Amore, P. A. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell. Biol. 105, 1455–1462 (1987).
Pietras, K. & Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23, 939–952 (2005).
Sun, J. et al. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24, 4701–4709 (2005).
Xian, X. et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116, 642–651 (2006). This study demonstrates that disruption of pericyte coverage from tumour vessels can elicit increased metastasis in a transgenic model of pancreatic islet carcinogenesis.
Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779–787 (2008).
Narayana, A. et al. Anti-angiogenic therapy using bevacizumab in recurrent high grade glioma: impact on local control and survival. J. Neurosurg. (in the press).
Berger, M. S. & Wilson, C. B. The Gliomas (W.B. Saunders, Philadelphia, 1999).
Kunkel, P. et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624–6628 (2001).
Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64, 8249–8255 (2004).
Lesslie, D. P. et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br. J. Cancer 94, 1710–1717 (2006).
Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963–969 (1997).
Marty, M. & Pivot, X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur. J. Cancer 44, 912–920 (2008).
Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
Sofuni, A. et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J. Gastroenterol. 40, 518–525 (2005).
Schneider, G. & Schmid, R. M. Genetic alterations in pancreatic carcinoma. Mol. Cancer 2, 15 (2003).
Cowgill, S. M. & Muscarella, P. The genetics of pancreatic cancer. Am. J. Surg. 186, 279–286 (2003).
Yu, J. L. et al. Heterogeneous vascular dependence of tumor cell populations. Am. J. Pathol. 158, 1325–1334 (2001).
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526–1528 (2002).
Kaur, B., Tan, C., Brat, D. J., Post, D. E. & Van Meir, E. G. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol. 70, 229–243 (2004).
Sessa, C., Guibal, A., Del Conte, G. & Ruegg, C. Biomarkers of angiogenesis in the development of antiangiogenic therapies in oncology: tools or decorations? Nature Clin. Pract. Oncol. 5, 378–391 (2008).
Wang, X. et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol. Cancer Ther. 2, 1085–1092 (2003).
Feng, Y. & Dimitrov, D. S. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr. Opin. Drug Discov. Devel. 11, 178–185 (2008).
Giaccia, A., Siim, B. G. & Johnson, R. S. HIF-1 as a target for drug development. Nature Rev. Drug Discov. 2, 803–811 (2003).
Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721–732 (2003).
Maxwell, P. H. The HIF pathway in cancer. Semin. Cell Dev. Biol. 16, 523–530 (2005).
Tan, C. et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65, 605–612 (2005).
Sarker, D. et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 14, 2075–2081 (2008).
Garrett, C. R. et al. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J. Clin. Oncol. 2007 ASCO Annu. Meeting Proc. Pt I 25, 14018 (2007).
Von Pawel, J. et al. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007 ASCO Annu. Meeting Proc. Pt I 25, 7635 (2007).
Acknowledgements
We thank R. Kerbel, M. Aghi, H. Rugo and O. Casanovas for insightful discussions. Research in the authors' laboratories was supported by grants from the US National Cancer Institute (to G.B. and D.H.), and by an award to D.H. from the William F. Bowes Charitable Foundation. D.H. is an American Cancer Society Research Professor and G.B. holds the Neill H. and Linda S. Brownstein Chair in Brain Tumour Research.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
National Cancer Institute
National Cancer Institute Drug Dictionary
FURTHER INFORMATION
Angiogenesis Inhibitors Therapy
Clinical trials in patients with brain cancer
Clinical trials in patients with breast cancer
Clinical trials in patients with gastrointestinal stromal tumours
Clinical trials in patients with kidney cancer
Clinical trials in patients with liver cancer
Clinical trials in patients with lymphoma
Clinical trials in patients with lung cancer
Glossary
- Hypertension
-
A medical condition in which the blood pressure is chronically increased.
- Doppler ultrasound
-
A test that uses reflected sound waves to evaluate blood flow.
- Hemangiocytes
-
CXCR4+ VEGFR1+ haematopoietic progenitors.
- Intravasation
-
Part of the metastasis process in which cancer cells invade through the basal membrane into blood vessels.
- Co-option
-
Blood vessel co-option: tumour cells grow around existing blood vessels in the tissue.
- Leptomeninges
-
The two innermost layers, comprised of the arachnoid mater and pia mater, that envelop the brain and spinal cord.
- Metronomic chemotherapy
-
Administration of chemotherapeutic drugs at comparatively low doses on a frequent or continuous schedule, with no extended interruptions.
- Oedema
-
An observable swelling due to an increase of interstitial fluid in any organ.
- Desmoplastic stroma
-
Abnormal and excessive growth of stromal cells that is often associated with invasive cancers.
Rights and permissions
About this article
Cite this article
Bergers, G., Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592–603 (2008). https://doi.org/10.1038/nrc2442
Issue Date:
DOI: https://doi.org/10.1038/nrc2442
This article is cited by
-
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R
Communications Chemistry (2024)
-
Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors
The EMBO Journal (2024)
-
Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma
Scientific Reports (2024)
-
Advances in the treatment of malignant ascites in China
Supportive Care in Cancer (2024)
-
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Journal of Translational Medicine (2023)